Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:ARLZ

Aralez Pharmaceuticals (ARLZ) Stock Price, News & Analysis

Aralez Pharmaceuticals logo

About Aralez Pharmaceuticals Stock (NASDAQ:ARLZ)

Advanced Chart
Remove Ads

Key Stats

Today's Range
$0.03
$0.03
50-Day Range
N/A
52-Week Range
$0.02
$2.98
Volume
N/A
Average Volume
5.13 million shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Aralez Pharmaceuticals Inc. operates as a specialty pharmaceutical company in the United States and Canada. It engages in acquiring, developing, and commercializing products in the areas of cardiovascular, pain management, dermatological allergy, and other indications. It offers Zontivity for the reduction of thrombotic cardiovascular events in patients with heart attack or peripheral arterial disease; Toprol-XL, a cardioselective beta-blocker that is indicated for the treatment of hypertension; Fibricor, a fenofibric acid for the treatment of severe hypertriglyceridemia and patients with primary hypercholesterolemia or mixed dyslipidemia; and Blexten, an antihistamine drug for the symptomatic relief of allergic rhinitis and chronic spontaneous urticarial. The company also markets Cambia, a non-steroidal anti-inflammatory drug (NSAID) for the acute treatment of migraine attacks; Soriatane for the treatment of severe psoriasis and other disorders of keratinization; Proferrin, an iron supplement; Fiorinal and Fiorinal C for the relief of tension type headaches; and Bezalip SR, a pan-peroxisome proliferator-activated receptor activator to treat hyperlipidemia, as well as to increase insulin sensitivity and decrease blood glucose levels for the patients with metabolic syndrome. In addition, it provides out-licensed products, which include VIMOVO for the relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, as well as to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers; and Treximet, a migraine medicine. The company was incorporated in 2015 and is headquartered in Mississauga, Canada.

Remove Ads
Receive ARLZ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aralez Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ARLZ Stock News Headlines

Adrian Adams's Net Worth
Trump’s Secret Weapon
Have you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's coming next. But here's the truth… This is just the beginning. Trump has made it clear his tariffs are coming, and that the market will get worse before it gets better. Luckily, our FREE Presidential Transition Guide details exactly what will happen in the next 100 days, and how to protect your hard-earned savings during these times. Don't wait for the next crash to wipe you out. Act now.
Amneal Pharmaceuticals, Inc. (AMRX)
Aveo Pharmaceuticals
MGC Pharmaceuticals Ltd (MXCM)
See More Headlines

ARLZ Stock Analysis - Frequently Asked Questions

Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) issued its quarterly earnings data on Thursday, November, 9th. The company reported ($0.37) EPS for the quarter, beating analysts' consensus estimates of ($0.39) by $0.02. The business's quarterly revenue was up 78.7% compared to the same quarter last year.

Based on aggregate information from My MarketBeat watchlists, some other companies that Aralez Pharmaceuticals investors own include Magnegas Applied Tchnlgy Sltns (MNGA), RedHill Biopharma (RDHL), Synergy Pharmaceuticals (SGYP), TransEnterix (TRXDW), Novavax (NVAX), Inovio Pharmaceuticals (INO) and Liquidmetal Technologies (LQMT).

Company Calendar

Last Earnings
11/09/2017
Today
4/03/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:ARLZ
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Optionable
Optionable
Beta
N/A
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for April 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (NASDAQ:ARLZ) was last updated on 4/3/2025 by MarketBeat.com Staff
From Our Partners